A Utilization Review of Patients That Respond to Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution

References

• Naltrexone hydrochloride. 2023. In Micromedex (Columbia Basin College Library ed.) [Electronic version]. Greenwood Village (CO): Truven Health Analytics. [accessed 2023 Feb 16]. http://www.micromedexsolutions.com/.
   Google Scholar
• Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–9. Epub 2018 Feb 23. PMID: 29377216. doi:10.1002/phar.2086.
   PubMed Web of Science ®Google Scholar
• Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–38. PMID: 23359310. doi:10.1002/art.37734.
   PubMed Web of Science ®Google Scholar
• Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep. 2020;24(10):64. PMID: 32845365. doi:10.1007/s11916-020-00898-0.
   PubMed Web of Science ®Google Scholar
• Rupp A, Young E, Chadwick AL. Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023;224(11):1270–81. PMID: 37302106; PMCID: PMC10628981. doi:10.1093/pm/pnad074.
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK, Hota D. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021;13(10):770–8. PMID: 34014028. doi:10.1111/1753-0407.13202.
   PubMed Web of Science ®Google Scholar
• Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016.
   PubMed Web of Science ®Google Scholar
• Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low dose naltrexone in the treatment of fibromyalgia. Curr Rheumatol Rev. 2018;14(2):177–80. doi:10.2174/1573397113666170321120329.
   PubMedGoogle Scholar
• Jackson D, Singh S, Zhang-James Y, Faraone S, Johnson B. The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. Front Psychiatry. 2021;12:593842. doi:10.3389/fpsyt.2021.593842.
   PubMed Web of Science ®Google Scholar
• Martin SJ, McAnally HB, Okediji P, Rogosnitzky M. Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study. Pain Manag. 2022;12(6):699–709. PMID: 35289682. doi:10.2217/pmt-2021-0122.
   PubMed Web of Science ®Google Scholar
• Hota D, Srinivasan A, Dutta P, Bhansali A, Chakrabarti A. Off-label, low-dose naltrexone for refractory painful diabetic neuropathy (Letter). Pain Med. 2016;17(4):790–1. doi:10.1093/pm/pnv009.
   PubMed Web of Science ®Google Scholar
• Ghai B, Bansal D, Hota D, Shah CS. Off-label, low-dose naltrexone for refractory chronic low back pain (Letter). Pain Med. 2014;15(5):883–4. doi:10.1111/pme.12345.
   PubMed Web of Science ®Google Scholar
• Sturm KM, Collin M. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients. Int J Pharm Compd. 2016;20(3):197–201.
   PubMedGoogle Scholar
• Weinstock LB, Myers TL, Walters AS, et al. Identification and treatment of new inflammatory triggers for complex regional pain syndrome: small intestinal bacterial overgrowth and obstructive sleep apnea. A A Case Rep. 2016;6(9):272–6.
   PubMedGoogle Scholar
• Chopra P, Cooper MS. Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013;8(3):470–6. doi:10.1007/s11481-013-9451-y.
   PubMed Web of Science ®Google Scholar
• Rivera V, DeCicco J, Espiritu S. Proceedings# 47: low dose naltrexone: a viable alternative for long term chronic pain? Brain Stimul. 2019;12(2):e118–20.
   Google Scholar
• Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option? Psychosomatics. 2012;53(6):591–4. doi:10.1016/j.psym.2011.11.006.
   PubMed Web of Science ®Google Scholar
• Raknes G, Småbrekke L. Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. a nationwide register-based controlled quasi-experimental before-after study. PLoS One. 2019;14(2):e0212460. doi:10.1371/journal.pone.0212460.
   PubMed Web of Science ®Google Scholar
• Beaudette-Zlatanova B, Lew RA, Otis JD, Branch-Elliman W, Bacorro E, Dubreuil M, Eyvazzadeh C, Kaur M, Lazzari AA, Libbey C, et al. Pilot study of low-dose naltrexone for the treatment of chronic pain due to arthritis: a randomized, double-blind, placebo-controlled, crossover clinical trial. Clin Ther. 2023;45(5):468–77. PMID: 37045708. doi:10.1016/j.clinthera.2023.03.013.
   PubMed Web of Science ®Google Scholar
• Colloca L. The placebo effect in pain therapies. Annu Rev Pharmacol Toxicol. 2019;59(1):191–211. PMID: 30216744; PMCID: PMC6402571. doi:10.1146/annurev-pharmtox-010818-021542.
   PubMedGoogle Scholar
• Rossettini G, Carlino E, Testa M. Clinical relevance of contextual factors as triggers of placebo and nocebo effects in musculoskeletal pain. BMC Musculoskelet Disord. 2018;19(1):27. PMID: 29357856; PMCID: PMC5778801. doi:10.1186/s12891-018-1943-8.
   PubMed Web of Science ®Google Scholar
• Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67(12):1716–23. doi:10.1136/ard.2008.092015.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
   Google Scholar